ANXA3 and neoplasm: The protein ANXA3, regardless of heterogeneity was found to have increased expression in NF2−/− tumours and showed promising results for personalised therapy driving attention to the development of a specific inhibitor that could support the treatment of patients with NF2−/− tumours.